MX2013011414A - Novedoso anticuerpo anti-receptor de il-23 humano. - Google Patents
Novedoso anticuerpo anti-receptor de il-23 humano.Info
- Publication number
- MX2013011414A MX2013011414A MX2013011414A MX2013011414A MX2013011414A MX 2013011414 A MX2013011414 A MX 2013011414A MX 2013011414 A MX2013011414 A MX 2013011414A MX 2013011414 A MX2013011414 A MX 2013011414A MX 2013011414 A MX2013011414 A MX 2013011414A
- Authority
- MX
- Mexico
- Prior art keywords
- human
- antibody
- receptor antibody
- novel anti
- seq
- Prior art date
Links
- 102100036672 Interleukin-23 receptor Human genes 0.000 title abstract 4
- 101710195550 Interleukin-23 receptor Proteins 0.000 title 1
- 108040001844 interleukin-23 receptor activity proteins Proteins 0.000 abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 101000853012 Homo sapiens Interleukin-23 receptor Proteins 0.000 abstract 1
- 230000009260 cross reactivity Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000008506 pathogenesis Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La invención tiene por objetivo proporcionar un anticuerpo anti-IL-23R humano que tiene excelente actividad y/o reactividad cruzada entre especies en comparación con anticuerpos anti-IL-23R humanos clásicos y proponer medios que utilizan los anticuerpos para prevenir o tratar varios tipos de enfermedades en las cuales están involucrado IL-23R humano en la patogénesis. Para este efecto, la invención propone un anticuerpo anti-IL-23R humano que contiene a la vez una región variable de cadena pesada hecha de una secuencia de aminoácidos expresada por la SEC ID NO: 5, 9, 13, 17, 21, 25 o 29, y una región variable de cadena ligera hecha de una secuencia de aminoácidos expresada por SEC ID NO: 7, 11, 15, 19, 23, 27 o 31.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011081982 | 2011-04-01 | ||
| PCT/JP2012/058531 WO2012137676A1 (ja) | 2011-04-01 | 2012-03-30 | 新規抗ヒトｉｌ－２３受容体抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013011414A true MX2013011414A (es) | 2014-04-14 |
| MX347955B MX347955B (es) | 2017-05-16 |
Family
ID=46969077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013011414A MX347955B (es) | 2011-04-01 | 2012-03-30 | Novedoso anticuerpo anti-receptor de il-23 humano. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9556276B2 (es) |
| EP (1) | EP2695897B1 (es) |
| JP (1) | JP5971238B2 (es) |
| KR (1) | KR20140032392A (es) |
| CN (2) | CN103459426B (es) |
| AR (1) | AR085824A1 (es) |
| BR (1) | BR112013024923A2 (es) |
| CA (1) | CA2831751A1 (es) |
| EA (1) | EA026119B1 (es) |
| ES (1) | ES2728438T3 (es) |
| MX (1) | MX347955B (es) |
| PL (1) | PL2695897T3 (es) |
| PT (1) | PT2695897T (es) |
| TR (1) | TR201908197T4 (es) |
| TW (1) | TW201249867A (es) |
| WO (1) | WO2012137676A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2821416T (pt) * | 2012-02-28 | 2018-12-14 | Astellas Pharma Inc | Anticorpo de recetor il-23 anti- humano inovador |
| CN104371019B (zh) * | 2013-08-13 | 2019-09-10 | 鸿运华宁（杭州）生物医药有限公司 | 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质 |
| AU2014370883B2 (en) | 2013-12-26 | 2020-09-24 | Mitsubishi Tanabe Pharma Corporation | Human anti-IL-33 neutralizing monoclonal antibody |
| SI3426680T1 (sl) * | 2016-03-10 | 2025-07-31 | Acceleron Pharma Inc. | Vezavni proteini receptorja aktivina tipa 2 in njihove uporabe |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| CN111471655B (zh) * | 2020-03-19 | 2023-07-07 | 湖州正熙医学检验实验室有限公司 | 抗人il12/23稳转细胞株及其构建方法和应用 |
| WO2023009891A2 (en) * | 2021-07-30 | 2023-02-02 | Janssen Biotech, Inc. | Materials and methods of making or using il-23r binding proteins |
| CN116948031A (zh) * | 2021-10-13 | 2023-10-27 | 浙江博锐生物制药有限公司 | 抗il-23r抗体及其用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| EP0690132B1 (en) | 1993-03-11 | 2003-12-17 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Anti-hiv monoclonal antibody |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JP5238723B2 (ja) * | 2007-02-28 | 2013-07-17 | メルク・シャープ・アンド・ドーム・コーポレーション | 操作された抗ｉｌ−２３ｒ抗体 |
| US20110158992A1 (en) * | 2008-08-27 | 2011-06-30 | Schering Corporation | Engineered Anti-IL-23R Antibodies |
| JP2012507723A (ja) * | 2008-11-03 | 2012-03-29 | シェーリング コーポレイション | 炎症性腸疾患生物マーカーおよび関連治療方法 |
-
2012
- 2012-03-08 TW TW101107919A patent/TW201249867A/zh unknown
- 2012-03-30 PL PL12767727T patent/PL2695897T3/pl unknown
- 2012-03-30 WO PCT/JP2012/058531 patent/WO2012137676A1/ja not_active Ceased
- 2012-03-30 JP JP2013508838A patent/JP5971238B2/ja not_active Expired - Fee Related
- 2012-03-30 PT PT12767727T patent/PT2695897T/pt unknown
- 2012-03-30 CA CA2831751A patent/CA2831751A1/en not_active Abandoned
- 2012-03-30 MX MX2013011414A patent/MX347955B/es active IP Right Grant
- 2012-03-30 EA EA201391453A patent/EA026119B1/ru not_active IP Right Cessation
- 2012-03-30 KR KR1020137028502A patent/KR20140032392A/ko not_active Abandoned
- 2012-03-30 US US14/007,030 patent/US9556276B2/en not_active Expired - Fee Related
- 2012-03-30 CN CN201280016918.4A patent/CN103459426B/zh not_active Expired - Fee Related
- 2012-03-30 EP EP12767727.6A patent/EP2695897B1/en active Active
- 2012-03-30 ES ES12767727T patent/ES2728438T3/es active Active
- 2012-03-30 TR TR2019/08197T patent/TR201908197T4/tr unknown
- 2012-03-30 AR ARP120101109A patent/AR085824A1/es unknown
- 2012-03-30 CN CN201510185222.XA patent/CN104817641B/zh not_active Expired - Fee Related
- 2012-03-30 BR BR112013024923A patent/BR112013024923A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN103459426A (zh) | 2013-12-18 |
| EP2695897A9 (en) | 2015-10-07 |
| EP2695897A1 (en) | 2014-02-12 |
| CN104817641B (zh) | 2018-06-26 |
| CN103459426B (zh) | 2015-05-13 |
| TW201249867A (en) | 2012-12-16 |
| PL2695897T3 (pl) | 2019-08-30 |
| AR085824A1 (es) | 2013-10-30 |
| EP2695897B1 (en) | 2019-05-01 |
| MX347955B (es) | 2017-05-16 |
| JPWO2012137676A1 (ja) | 2014-07-28 |
| US9556276B2 (en) | 2017-01-31 |
| EA026119B1 (ru) | 2017-03-31 |
| PT2695897T (pt) | 2019-06-12 |
| KR20140032392A (ko) | 2014-03-14 |
| WO2012137676A1 (ja) | 2012-10-11 |
| CN104817641A (zh) | 2015-08-05 |
| ES2728438T3 (es) | 2019-10-24 |
| US20140275490A1 (en) | 2014-09-18 |
| TR201908197T4 (tr) | 2019-06-21 |
| EP2695897A4 (en) | 2015-03-18 |
| JP5971238B2 (ja) | 2016-08-17 |
| BR112013024923A2 (pt) | 2016-11-22 |
| CA2831751A1 (en) | 2012-10-11 |
| EA201391453A1 (ru) | 2014-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2013011414A (es) | Novedoso anticuerpo anti-receptor de il-23 humano. | |
| NZ706377A (en) | Il-6 antagonists and uses thereof | |
| NZ610734A (en) | Human antibodies to the glucagon receptor | |
| EA035160B9 (ru) | Антитела к st2 и их применение | |
| NZ703653A (en) | Anti-fap antibodies and methods of use | |
| NZ600768A (en) | Human antibodies to human angiopoietin-like protein 4 | |
| RU2017129721A (ru) | АНТИТЕЛА ПРОТИВ αβTCR | |
| MX348578B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
| NZ628943A (en) | Human antibodies to clostridium difficile toxins | |
| SI2771031T1 (en) | Humanized antibodies that recognize alpha-synuclein | |
| NZ610294A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
| EA201990171A1 (ru) | Биспецифичное антитело против egfr и против cd3 и его применения | |
| MY177098A (en) | Novel anti-human tslp receptor antibody | |
| NZ607969A (en) | Cd33 binding agents | |
| NZ603226A (en) | Anti-c5a antibodies and methods for using the antibodies | |
| PE20141147A1 (es) | Anticuerpos a pcsk9 y usos de los mismos | |
| NZ610091A (en) | Antibodies | |
| PH12014500089A1 (en) | Antibodies that bind to ox40 and their uses | |
| PE20141028A1 (es) | Nuevos moduladores y metodos para su uso | |
| NZ629296A (en) | Humanized antibodies that recognize alpha-synuclein | |
| MX341958B (es) | Anticuerpos contra el il33r humano y usos de los mismos. | |
| MX2016008520A (es) | Anticuerpo bdca-2 antihumano novedoso. | |
| EA201490433A1 (ru) | Новое антитело против ngf человека | |
| AU2015287227A8 (en) | Immune-stimulating monoclonal antibodies against human interleukin-2 | |
| NZ594682A (en) | Fully human antibodies specific to cadm1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |